Share on LinkedInShare on LinkedIn

ARTICLE · 01 APRIL 2015

Federal Court Judge Dismisses Final Prohibition Application In CIALIS PM(NOC) Proceeding

McCarthy Tétrault
McCarthy Tétrault
Contributor
McCarthy Tétrault

McCarthy Tétrault

McCarthy Tétrault LLP provides a broad range of legal services, delivering strategic and...

View firm profile
Explore more from McCarthy Tétrault

On February 23, 2015, the Federal Court released its judgment in the latest of three PM(NOC) proceedings relating to Eli Lilly’s CIALIS (tadalafil) patents.

CanadaIntellectual Property

On February 23, 2015, the Federal Court released its judgment in the latest of three PM(NOC) proceedings relating to Eli Lilly's CIALIS (tadalafil) patents. The previous two decisions were discussed in snIP/ITs posted on January 26, 2015 and March 30, 2015.

In the latest decision, Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2015 FC 178, Justice de Montigny found that Mylan's allegations of non-infringement and obviousness were justified, and dismissed Lilly's application for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Mylan until expiry of Canadian Patent No 2,379,948 (the "'948 Patent"). The '948 Patent claims a tadalafil tablet formulation and its use to treat erectile dysfunction ("ED").

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from